Physician profile
Daniel Adeneye
NPI 1770929929
$786.22
in general payments reported to CMS, 2019-2025
11 companies · $324 in 2025
The $324 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.27 · 2020: $48.97 · 2021: $76.71 · 2022: $15.33 · 2023: $135 · 2024: $169 · 2025: $324.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542 · Education: $86.05.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $541.89 |
| Education | $86.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $157.05 | 2020-2025 | Lokelma, Farxiga |
| Akebia Therapeutics INC | $148.30 | 2025 | Vafseo |
| Amgen INC. | $139.50 | 2023-2025 | Tavneos |
| Bayer Healthcare Pharmaceuticals INC. | $97.27 | 2024-2025 | |
| Lilly USA, LLC | $61.67 | 2024-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $54.38 | 2019-2025 | Jynarque, Voyxact |
| Calliditas Therapeutics US INC. | $43.20 | 2023-2024 | Tarpeyo |
| Fresenius USA Marketing, INC. | $30.65 | 2022-2024 | Velphoro |
| Ardelyx, INC. | $28.37 | 2025 | Ibsrela |
| Glaxosmithkline, LLC. | $14.16 | 2021 | |
| Alexion Pharmaceuticals, INC. | $11.67 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Adeneye listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.